ReviewNature reviews. Microbiology2023
The effects of the COVID-19 pandemic on community respiratory virus activity.
Review in Nature reviews. Microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06309212 (Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults), which is not on this map. Cited by 481 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults
Who cites it
481 citing papers in PubMed, 3 syntheses or guidelines pooled it, 640 citations in OpenAlex.
- Clinical manifestations and laboratory findings in patients coinfected with dengue virus and SARS-CoV-2: a systematic review.BMC infectious diseases · 2026Pooled it
- Prevalence of common respiratory viruses of infants with respiratory tract infections in European countries in the past decade: a systematic review and meta-analysis comparing between the pre-COVID-19, pandemic, and post-COVID-19 periods.European journal of pediatrics · 2026Pooled it
- The Global Prevalence of and Factors Associated with Parasitic Coinfection in People Living with Viruses: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2025Pooled it
- Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infection.Emerging microbes & infections · 2026Article
- Symptom-based diagnostic models for common respiratory viral infections: a machine learning and natural language processing study.Infectious Disease Modelling · 2026Article
- What shapes influenza attitudes and behaviors in Italy? Insights from a cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Metabolic control of macrophages in coronavirus disease 2019.Virulence · 2026Review
- Observed Clinical and Operational Factors Are Associated with Biomarker Test Utilization in Respiratory Virus RT-PCR Testing: A Real-World Analysis of Inflammatory, Cardiac, and Thrombotic Biomarkers.Diagnostics (Basel, Switzerland) · 2026Article
- Cardiovascular and mortality risks following COVID-19-related versus non-COVID-19-related chronic obstructive pulmonary disease exacerbations.Annals of the American Thoracic Society · 2026Article
- Monitoring influenza-like symptoms in the UK through participatory surveillance: Insights from FluSurvey over two winter seasons (2023-24 and 2024-25).PLOS digital health · 2026Article
- Regional inequality in infant RSV morbidity and mortality burden in the era of expanded RSV passive immunisation: a global projection modelling study.EClinicalMedicine · 2026Article
- Postpandemic Trends in Pediatric Respiratory Virus Hospitalizations: A Multicenter Study, 2019-2025.Influenza and other respiratory viruses · 2026Article
- Increased respiratory pathogen positivity and diversity in hospitalized children following the COVID-19 pandemic in Malaysia.New microbes and new infections · 2026Article
- Delayed Seasonality but Consistent Age Burden: RSV Epidemiology Pre-, During, and Post-COVID-19 Pandemic on the Kenyan Coast (2008-2026).Open forum infectious diseases · 2026Article
- Genomic surveillance of SARS-CoV-2 in Tunisia during the omicron era: insights from the national influenza & other respiratory viruses laboratory.Virology journal · 2026Article
- Epidemiology and severity of pediatric influenza hospitalizations before and during the COVID-19 pandemic: a surveillance study of the Canadian immunization monitoring program (IMPACT), 2012-2023.Lancet regional health. Americas · 2026Article
- Epidemiology of SARS-CoV-2, Influenza, RSV, and Human Metapneumovirus Across the COVID-19 Era: An Eight-Year Tertiary-Center Study in Saudi Arabia.Pathogens (Basel, Switzerland) · 2026Observational
- Article
- Seasonal Distribution, Virus-Specific Hematologic Profiles, and Predictors of Hospitalization in Children with Respiratory Viral Infections.Children (Basel, Switzerland) · 2026Article
421 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused substantial global morbidity and deaths, leading governments to turn to non-pharmaceutical interventions to slow down the spread of infection and lessen the burden on health care systems. These policies have evolved over the course of the COVID-19 pandemic, including after the availability of COVID-19 vaccines, with regional and country-level differences in their ongoing use. The COVID-19 pandemic has been associated with changes in respiratory virus infections worldwide, which have differed between virus types. Reductions in respiratory virus infections, including by influenza virus and respiratory syncytial virus, were most notable at the onset of the COVID-19 pandemic and continued in varying degrees through subsequent waves of SARS-CoV-2 infections. The decreases in community infection burden have resulted in reduced hospitalizations and deaths associated with non-SARS-CoV-2 respiratory infections. Respiratory virus evolution relies on the maintaining of a diverse genetic pool, but evidence of genetic bottlenecking brought on by case reduction during the COVID-19 pandemic has resulted in reduced genetic diversity of some respiratory viruses, including influenza virus. By describing the differences in these changes between viral species across different geographies over the course of the COVID-19 pandemic, we may better understand the complex factors involved in community co-circulation of respiratory viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.